Posted by Michael Wonder on 18 Jul 2024
Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of rucaparib camsylate in the NHS in England.
Rucaparib camsylate is recommended as an option for the maintenance treatment of adults with advanced (International Federation of Gynecology and Obstetrics stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
